CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 6039 result(s)

emicizumab (Hemlibra)

Last Updated: June 2, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: emicizumab
Indications: Bleeding prevention, hemophilia A

  • Brand Name: Hemlibra
  • Manufacturer: Hoffmann-La Roche Ltd.
  • Project Number: ST0651-000
  • Project Status: Pending
  • Submission Type: New

Management of Lyme Disease: Recommendations for Diagnosis, Treatment, and Post-Exposure Prophylaxis

Last Updated: June 2, 2020
Result type: Reports
Product Line: INESSS

Lyme disease is an emerging vector-borne disease in some parts of Canada. Management of Lyme disease is challenging, complicated by an array of clinical presentations and limited evidence supporting diagnostic and treatment strategies. Recommendations and clinical decision support tools for the management of localized and disseminated Lyme disea...

dupilumab (Dupixent)

Last Updated: June 1, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: dupilumab
Indications: atopic dermatitis

  • Brand Name: Dupixent
  • Manufacturer: Sanofi Genzyme, a division of sanofi-aventis Canada Inc.
  • Project Number: SR0636-000
  • Project Status: Active
  • Submission Type: New

budesonide (Jorveza)

Last Updated: June 1, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: budesonide
Indications: Eosinophilic esophagitis, adults

  • Brand Name: Jorveza
  • Manufacturer: AVIR Pharma Inc.
  • Project Number: SR0634-000
  • Project Status: Active
  • Submission Type: New

esketamine hydrochloride (Spravato)

Last Updated: June 1, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: esketamine hydrochloride
Indications: Major depressive disorder (MDD), adults

  • Brand Name: Spravato
  • Manufacturer: Janssen Inc.
  • Project Number: SR0621-000
  • Project Status: Active
  • Submission Type: New

burosumab (Crysvita)

Last Updated: November 28, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: burosumab
Indications: Treatment of X-Linked Hypophosphatemia

  • Brand Name: Crysvita
  • Manufacturer: Kyowa Kirin Limited
  • Project Number: SR0602-000
  • Project Status: Active
  • Submission Type: New

CADTH Weekly COVID-19 Update

Last Updated: June 1, 2020
Result type: Reports
Product Line: New at CADTH

Introducing our newly redesigned COVID-19 Evidence Portal featuring more information and new search capabilities. CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time. Our COVID-19 evidence portal contains the latest COVID-19 information from CADTH and other respected organizations. ...